Evidence map›Paper›PMID 42353287›Full record

ArticleInternational journal of molecular sciences2026

Systemic AAV-h

Su Jin Kim, Yu Hwa Nam, Eun Young Joo, Jisun Park, Saeyoung Park, Sung-Chul Jung, Dong-Kyu Jin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Su Jin KimDepartment of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea.ORCID 0000-0003-0893-0512
Yu Hwa NamDepartment of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
Eun Young JooDepartment of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea.ORCID 0009-0002-5972-6191
Jisun ParkDepartment of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea.
Saeyoung ParkDepartment of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.ORCID 0000-0003-3374-3911
Sung-Chul JungDepartment of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.ORCID 0000-0002-3174-8965
Dong-Kyu JinSchool of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.

Funding

Inha University 75440-1
6 · The paper itself

Abstract

Glutaric aciduria type 1 (GA1) is a rare neurometabolic disorder caused by glutaryl-CoA dehydrogenase (GCDH) deficiency, leading to the accumulation of neurotoxic metabolites that can cause both acute encephalopathic crises and progressive, insidious brain injury. Current management primarily relies on a protein-restricted diet, which remains therapeutically insufficient and burdensome for patients, highlighting the need for disease-modifying therapies. In this study, we established a novel GA1 mouse model using CRISPR/Cas9 technology and evaluated the preclinical efficacy of systemic recombinant adeno-associated virus (rAAV)-mediated gene therapy. Under standard dietary conditions without high-lysine challenge, our GA1 model exhibited sustained cerebral and hepatic glutaric acid (GA) accumulation and distinct chronic vacuolation in the hippocampus and cerebellum, mirroring the insidious-onset GA1 phenotype. Five-week-old mice received a single intravenous injection of rAAV-h

Indexed as

Amino Acid Metabolism, Inborn ErrorsBrainBrain Diseases, MetabolicDependovirusGenetic TherapyGlutaratesGlutaryl-CoA DehydrogenaseAnimalsCRISPR-Cas SystemsDisease Models, AnimalGene Therapy AgentsGenetic VectorsLiverMaleMiceGlutaratesglutaric acidGlutaryl-CoA Dehydrogenaseadeno-associated virusCRISPR/Cas9 mouse modelgene therapyglutaric aciduria type 1glutaryl-CoA dehydrogenaseneurometabolic disease

Identifiers

PMID42353287
PMCPMC13299285

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.